Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

To fate of exogenous glucagon-like peptide I (GLP-I)(7–36) amide was studied in nondiabetic and type II diabetic subjects using a combination of high-pressure liquid chromatography (HPLC), specific radioimmunoassays (RIAs), and a sensitive enzyme-linked immunosorbent assay (ELISA), whereby intact biologically active GLP-I and its metabolites could be determined. After GLP-I administration, the intact peptide could be measured using an NH2-terminally directed RIA or ELISA,while the difference in concentration between these assays and a COOH-terminal–specific RIA allowed determination of NH2-terminally truncated metabolites. Subcutaneous GLP-I was rapidlydegraded in a time-dependent manner, forming a metabolite, which co-eluted on HPLC with GLP-I(9–36) amide and had the same immunoreactive profile. Thirty minutes after subcutaneous GLP-I administration to diabetic patients (n = 8), the metabolite accounted for 88.5 ± 1.9% of the increase in plasma immunoreactivity determined by the COOH-terminal RIA, which was higher than the levels measured in healthy subjects (78.4 ± 3.2%; n = 8; P < 0.05). Intravenously infused GLP-I was also extensively degraded, but no significant differences were seen between the two groups. Intact GLP-I accounted for only 19.9 ± 3.4% of the increase in immunoreactivity measured with the COOH-terminal RIA in normal subjects (n = 8), and 25.0 ± 4.8% of the increase in diabetic subjects (n = 8), the remainder being the NH2-terminally truncated metabolite.

[1]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[2]  M. Kobusiak-Prokopowicz.  [Angiotensin converting enzyme inhibitors for hypertension]. , 1997, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[3]  J. Wharton,et al.  The natriuretic peptide family: turning hormones into drugs. , 1993, The Journal of endocrinology.

[4]  D. Nathan,et al.  Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects , 1992, Diabetes Care.

[5]  J. Holst.  Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin--current status. , 1983, Gastroenterology.

[6]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[7]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[8]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[9]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[10]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[11]  C. Orskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis. , 1992, Diabetologia.

[12]  P. Layer,et al.  Is GLP-1 amide an endogenous antagonist at GLP-1 receptors? , 1994 .

[13]  G. Weir,et al.  Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats. , 1993, Metabolism: clinical and experimental.

[14]  J. Holst,et al.  Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. , 1994, Metabolism: clinical and experimental.

[15]  G. Waeber,et al.  Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM , 1993, Diabetes.

[16]  J. Holst,et al.  Proglucagon processing in porcine and human pancreas. , 1994, The Journal of biological chemistry.

[17]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[18]  I. Valverde,et al.  Renal catabolism of truncated glucagon-like peptide 1. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[19]  G. Weir,et al.  Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas , 1989, Diabetes.